Drug Regulation

Orange Book & Inaccurate Patents: US Federal Trade Commission in Action

/ By / Data Exclusivity, Drug Regulation, Patent

[This post is co-authored by SpicyIP Intern Pranav Aggarwal and Swaraj Paul Barooah. Pranav is a second-year student pursuing B.A.LL.B.(Hons) at Rajiv Gandhi National University of Law, Punjab. He has a keen interest in commercial laws, especially in IP and allied fields. His previous posts can be accessed here.] On 7th November 2023, the Federal Trade Commission (“FTC”) issued a press release announcing its challenge to more than 100 patents listed in the ‘Orange Book’. These patents which belong to ten […]

Orange Book & Inaccurate Patents: US Federal Trade Commission in Action Read More »

SpicyIP Weekly Review (January 29- February 04)

/ By / Copyright, Drug Regulation, Patent, Trademark

After an eventful week, here is our recap of its top IP developments. Last week we published 9 posts on topics such as the proposed Patent (2nd Amendment) Rules, the Delhi High Court-Butter Chicken Controversy, and developments regarding the public search and e-register feature of the TMR website. Don’t forget to check them out on the blog too! Highlights of the Week Comments on the Proposed Patent (2nd Amendment) Rules, 2024 In addition to the typos and ambiguity regarding the

SpicyIP Weekly Review (January 29- February 04) Read More »

Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (September 11- September 17)

/ By / Copyright, Drug Regulation, Others, Patent, Trademark

Wondering what IP developments took place last week? Look no further as we present to you the SpicyIP Weekly Review, highlighting the discussions that took place on the blog along with other IP news.   Highlights of the Week Draft Patent Amendment Rules – Increasing Efficiency of Granting Patent Monopolies While Forgetting the Reason for Allowing Them in the First Place Changing substantive safeguards through procedural amendments. That’s perhaps the best way to summarize the recently proposed Draft Patent Amendment Rules.

SpicyIP Weekly Review (September 11- September 17) Read More »

Toothless National Policy on Rare Diseases- Part II

/ By / Drug Regulation, Patent

[This guest post is authored by our former blogger Varsha Jhavar and Surbhi Nautiyal. Varsha is a lawyer based in Delhi and is a graduate of Hidayatullah National Law University, Raipur.  Surbhi is a lawyer based in Delhi and is a graduate of RGSOIPL, IIT Kharagpur. The views expressed here are those of the authors’ alone.] In Part I of the post, the authors have analysed the National Policy on Rare Diseases, 2021 (Policy) and its implementation. In Part II,

Toothless National Policy on Rare Diseases- Part II Read More »

Toothless National Policy on Rare Diseases – Part I

/ By / Drug Regulation, Patent

[This guest post is authored by our former blogger Varsha Jhavar and Surbhi Nautiyal. Varsha is a lawyer based in Delhi and is a graduate of Hidayatullah National Law University, Raipur.  Surbhi is a lawyer based in Delhi and is a graduate of RGSOIPL, IIT Kharagpur. The views expressed here are those of the authors’ alone.] At the Delhi High Court’s (DHC) bidding, major developments have taken place in the rare diseases space in India. These include the introduction of

Toothless National Policy on Rare Diseases – Part I Read More »

Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review ( August 14 – August 20)

/ By / Copyright, Drug Regulation, Patent, Plant Variety Protection, Trademark

Last week was full of exciting discussions on the blog. Niyati wrote on the Delhi High Court order rejecting the appeal against Pepsico’s potato plant variety revocation order. Aparajita wrote on the potential impact of the recently passed Jan Vishwas Bill, 2023. We also had a guest post by Aditya Gupta on the Delhi High Court Division Bench’s order in Google v. DRS Logistics. Anything important we’re missing out on? Drop us a comment below!  This Weekly Review is co-authored

SpicyIP Weekly Review ( August 14 – August 20) Read More »

Special 301 Report 2023: Reflections from Public Health Perspective

/ By / Drug Regulation, Others, Patent

The US Trade Representative (USTR) released the Special 301 Report for 2023 on April 26, 2023, and has placed India in the ‘Priority Watch List’, yet again. The Special 301 Report is a unilateral measure whereby the identified countries, whose IP regimes are not in line with the trading interests of the US industries, are placed a threat of unilateral sanctions. India, which has featured in this list multiple times in the past, (as highlighted on the blog by different

Special 301 Report 2023: Reflections from Public Health Perspective Read More »

SpicyIP Weekly Review (March 6- March 11)

/ By / Biological Diversity, Copyright, COVID-19, Drug Regulation, Geographical Indication, Patent, Trademark

Here are the quick summaries of 5 posts, 4 case summaries and other IP developments that took place last week. Important IP cases that we’re missing out on? Especially from other High Courts?  Please let us know so we can include them!   Highlights of the Week Learning from India’s Disastrous Experience in Protecting Itself against Biopiracy In light of the upcoming WIPO Diplomatic Conference on Genetic Resources and Traditional Knowledge, Prashant Reddy brings us a post highlighting India’s sub-par experience with

SpicyIP Weekly Review (March 6- March 11) Read More »

SpicyIP Tidbit: Delhi HC passes ex parte injunction in favour of Glenmark in ‘TELMA / TELMA-AM’ counterfeiting claim

/ By / Drug Regulation, Trademark

The Delhi High Court passed an ex parte injunction in the matter of Glenmark Pharmaceuticals vs Sanjeevni Medicos And Or against the defendant and restrained them from manufacturing, marketing, selling, and advertising medicinal and pharmaceutical preparations under Glenmark’s trade mark – ‘TELMA’ and ‘TELMA-AM’ and any other mark deceptively similar to the same. The injunction was granted to prevent confusion or deception amounting to infringement or passing off of Glenmark’s trade mark registrations. Telma and Telma-AM are trademarked names for

SpicyIP Tidbit: Delhi HC passes ex parte injunction in favour of Glenmark in ‘TELMA / TELMA-AM’ counterfeiting claim Read More »

SpicyIP Weekly Review (January 10- January 16)

/ By / Competition Law, Copyright, Design, Drug Regulation, Patent, Trademark

After another busy week here at SpicyIP, we bring out the quick summaries of the 6 blogposts that were put up, along with 12 case summaries and national and international IP developments for you. Important IP cases that we’re missing out on? Especially from other High Courts? Please let us know so we can include them!   Highlights of the Week Bill to Decriminalise IP Offences Misses the Mark and Dilutes Significant Provisions Discussing the proposed amendments to the IP

SpicyIP Weekly Review (January 10- January 16) Read More »

Scroll to Top